4.7 Article

Osteocrin, a novel myokine, prevents diabetic cardiomyopathy via restoring proteasomal activity

Journal

CELL DEATH & DISEASE
Volume 12, Issue 7, Pages -

Publisher

SPRINGERNATURE
DOI: 10.1038/s41419-021-03922-2

Keywords

-

Categories

Funding

  1. National Natural Science Foundation of China [81700254]
  2. Key Project of the National Natural Science Foundation [81530012]
  3. National Key R&D Program of China [2018YFC1311300]
  4. Fundamental Research Funds for the Central Universities [2042018kf1032]
  5. Development Center for Medical Science and Technology National Health and Family Planning Commission of the People's Republic of China (The prevention and control project of cardiovascular disease) [2016ZX-008-01]
  6. Science and Technology Planning Projects of Wuhan [2018061005132295]

Ask authors/readers for more resources

Proteasomal activity is compromised in diabetic hearts, leading to proteotoxic stresses and cardiac dysfunction. Osteocrin (OSTN) plays a crucial role in diabetic cardiomyopathy (DCM) by maintaining the dephosphorylation state of protein kinase B/FOXO1 to alleviate cardiac injury. Experimental evidence demonstrates that OSTN can restore PKB-dependent proteasomal function, providing protective effects against diabetic heart damage.
Proteasomal activity is compromised in diabetic hearts that contributes to proteotoxic stresses and cardiac dysfunction. Osteocrin (OSTN) acts as a novel exercise-responsive myokine and is implicated in various cardiac diseases. Herein, we aim to investigate the role and underlying molecular basis of OSTN in diabetic cardiomyopathy (DCM). Mice received a single intravenous injection of the cardiotrophic adeno-associated virus serotype 9 to overexpress OSTN in the heart and then were exposed to intraperitoneal injections of streptozotocin (STZ, 50 mg/kg) for consecutive 5 days to generate diabetic models. Neonatal rat cardiomyocytes were isolated and stimulated with high glucose to verify the role of OSTN in vitro. OSTN expression was reduced by protein kinase B/forkhead box O1 dephosphorylation in diabetic hearts, while its overexpression significantly attenuated cardiac injury and dysfunction in mice with STZ treatment. Besides, OSTN incubation prevented, whereas OSTN silence aggravated cardiomyocyte apoptosis and injury upon hyperglycemic stimulation in vitro. Mechanistically, OSTN treatment restored protein kinase G (PKG)-dependent proteasomal function, and PKG or proteasome inhibition abrogated the protective effects of OSTN in vivo and in vitro. Furthermore, OSTN replenishment was sufficient to prevent the progression of pre-established DCM and had synergistic cardioprotection with sildenafil. OSTN protects against DCM via restoring PKG-dependent proteasomal activity and it is a promising therapeutic target to treat DCM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available